REGN
CompareRegeneron Pharmaceuticals Inc
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Profit margin of 31.4% — that's well above average.
Current Price
$766.02
+2.60%GoodMoat Value
$1382.84
80.5% undervaluedRegeneron Pharmaceuticals Inc (REGN) Quality Analysis
REGN Profitability
REGN Growth
REGN Financial Health
REGN Quality & Fundamental Analysis
Regeneron Pharmaceuticals Inc (REGN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Regeneron Pharmaceuticals Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Regeneron Pharmaceuticals Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 31.41% and a return on equity (ROE) of 14.41%. Return on assets (ROA) stands at 11.11%.
The debt-to-equity ratio is 0.09, with a current ratio of 4.13. Operating margin is 24.95%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Regeneron Pharmaceuticals Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.